

Index

A

Acinic cell carcinoma (ACC), 133, 146
Acute mastitis, 7, 49
Adenoid cystic carcinoma, 133, 147
Adenomyoepithelioma, 70
Adenosis, 62
ADH. *See* Atypical ductal hyperplasia (ADH)
ALH. *See* Atypical lobular hyperplasia (ALH)
Anastomosing capillaries, 116
Anatomy, 1
Angiosarcoma, 26
Apocrine adenosis, 62
Apocrine carcinomas, 25, 133, 144, 146
Apocrine cells, 58
Apocrine metaplasia, 9, 91, 145
Aspiration, 35–37
Asymmetric density, 83
Atypical ductal hyperplasia (ADH), 16, 63, 90–94, 179
Atypical epithelial hyperplasia, 16, 108, 180
Atypical epithelial proliferations, 90–98
Atypical lobular hyperplasia (ALH), 16, 90, 96
Axillary lymph node dissection (ALND), 151

B

Basal, 163
Basal-like tumors, 172
Bcl2, 166
Benign papillary lesions, 114
Benign phyllodes tumor, 12
Bipolar nuclei, 65, 80, 101, 104, 108, 119
Blue dye, 151
Blunt duct adenosis, 62
BRCA1 mutation, 140, 172
Breast
 abscesses, 49
 augmentation, 8

C

Calcifications, 83, 94, 96, 101, 109, 115, 120, 123, 178
Cancers, 70
Carcinoma
 with medullary features, 139
 with mesenchymal differentiation, 132
Cell block, 44–48, 186

Cellular cohesion, 100
Cellular fibroadenoma, 71
Cellularity, 103, 115, 116, 124
Cellular monotony, 91
Chromogranin., 117
Chronic mastitis, 9
CISH, 172
CK5/6, 128, 163
CK8/18, 163
CK14, 128
Clear cell carcinoma, 147
Clinical presentation, 7
CNB. *See* Core needle biopsy (CNB)
Columnar cell changes, 16, 83, 85, 87–89, 108–110
Columnar cell hyperplasia, 16
Complex fibroadenomas, 10, 71
Complex sclerosing lesion, 63
Complications of breast FNAC, 41
Core needle biopsy (CNB), 83, 177
Cribriform
 carcinoma, 132
 patterns, 91, 99, 115, 120
Crush artifact, 80
Cyclin D1, 160
Cysts, 57, 58, 62
Cytologic grading, 73–77
Cytoplasmic apical snouts, 89
Cytoplasmic vacuolation, 101

D

DCIS. *See* Ductal carcinoma in situ (DCIS)
Diabetic mastopathy, 11, 54, 55
Ductal carcinoma, 90
Ductal carcinoma in situ (DCIS), 16, 18, 91, 92, 94–96,
 99–101, 179, 180
Ductal cells, 58
Duct ectasia, 8, 50–51, 55

E

E-cadherin, 163
Elastoid stromal fragments, 101
Encapsulated papillary carcinoma, 119–121, 127
Encysted papillary carcinoma, 119–121
Epithelial hyperplasia, 16, 63, 83, 84, 108

- Epithelial proliferation, 103
 Epithelioid myoepithelial cells, 70
 Estrogen receptor (ER), 128, 163, 171, 173
 ETV6 gene rearrangements, 147
- F**
 False-negative, 85, 90, 137, 138, 163
 False-positive, 85, 143, 163
 Fat necrosis, 8, 54–55
 FCC. *See* Fibrocystic changes (FCC)
 FEA. *See* Flat epithelial atypia (FEA)
 Fibroadenomas, 10, 65, 78, 181
 Fibrocystic changes (FCC), 9, 57, 104, 106
 Fibroepithelial lesions, 178, 181
 Fibromatosis, 142
 Fibromatosis-like metaplastic carcinoma, 132
 Fibrovascular cores, 103, 106, 111, 112
 FISH, 172
 Fixation, 39
 Flat epithelial atypia (FEA), 16, 90
 Florid epithelial hyperplasia, 83, 85–87, 91, 180
 Florid hyperplasia, 63, 87
- G**
 Gamma probe, 151
 Glands, 1
 Glandular formation, 98
 Glycogen-rich carcinomas, 133, 146, 147
 Grading, 101
 Granulomatous mastitis, 51–54
- H**
 Hamartoma, 11, 69, 78
 HER2, 163, 164, 171, 173
 HER2 amplification, 172
 HER2/neu, 164
 High-grade DCIS, 18
 Hormone receptors, 163
 Hyaline globules, 148
- I**
 Idiopathic granulomatous mastitis, 9, 52, 55
 ILC. *See* Invasive lobular carcinoma (ILC)
 Immunocytochemistry, 172
 Immunohistochemistry, 159, 186
 Inadequacy rates, 178
 Indeterminate calcifications, 57
 Infarction, 106
 Inflammatory carcinoma, 25
 In situ hybridization (ISH), 169
 Intracystic papillary carcinoma, 21, 112, 119–121
 Intracytoplasmic lumina, 134
 Intracytoplasmic vacuoles, 97
 Intracytoplasmic vacuolization, 146
 Intraduct papilloma, 70, 104–112
 Invasion, 96, 179
 Invasive breast carcinoma, 131
 of no special type, 134–136
 Invasive carcinoma, 99
 Invasive cribriform carcinoma, 137
 Invasive ductal carcinoma (IDC), 132
 not otherwise specified (NOS), 21
 Invasive lobular carcinoma (ILC), 22, 132, 136, 163
 Invasive low-grade ductal carcinoma, 115
 Invasive micropapillary carcinoma, 25, 132, 141–142
 ISH. *See* In situ hybridization (ISH)
- J**
 Juvenile fibroadenoma, 65, 71
 Juvenile papillomatosis, 107
- K**
 Ki-67, 159
- L**
 Lactating adenoma, 146
 Lactation, 3–4
 LCIS. *See* Lobular carcinoma in situ (LCIS)
 Lesion localization, 34–35
 Lipid-rich carcinoma, 133, 147
 Liquid-based cytology, 43–44, 170
 Lobular carcinoma, 90
 Lobular carcinoma in situ (LCIS), 18, 90, 96
 Lobular neoplasia, 90, 96–98, 163
 Low-grade adenosquamous carcinoma, 132
 Low-grade carcinoma in situ, 115
 Low-grade DCIS, 90
 Luminal A, 163
 Luminal B, 163
 Lymphedema, 151
- M**
 Malignant lymphoma, 141
 Malignant phyllodes tumor, 12, 26
 Medullary carcinoma, 24, 132
 Menarche, 2
 Menopause, 4–5
 Menstrual cycle, 2
 Meshwork tissue fragments, 104
 Metaplastic breast carcinomas (MBC), 142
 Metaplastic carcinomas, 25, 132
 Metastatic breast cancer, 173
 Metastatic tumors, 27
 Microcalcifications, 103, 112
 angulated, 112
 psammomatous, 112
 Microglandular adenosis, 15, 60, 62
 differentiation from tubular carcinoma, 62
 Micropapillary, 91, 103, 120
 Mitotic figures, 96

- Moderate hyperplasia, 86, 87
Molecular classification, 163, 170–171
Molecular techniques, 169
Montgomery, 1
Mucin, 123, 125, 127, 132
Mucinous carcinoma, 22, 124–126, 132, 138
 type A, 126
 type AB, 126
 type B, 126
Mucinous lesions, 123–129
Mucinous papillary neoplasms, 127–129
Mucocele-like lesions, 69, 123–124
Multinucleated giant cells, 50, 142
Myoepithelial cells, 58, 99, 100, 108, 115, 119, 135, 160
Myxoid
 background, 142
 fibroadenoma, 129
- N**
Necrosis, 96, 98, 101, 115, 132
Necrotic, 120
Needle biopsy, 177
Neoadjuvant therapy, 173
Neuroendocrine, 125, 128
 differentiation, 23
 markers, 117
Nipple inversion, 50
Nodular fasciitis, 142
Non-palpable, 178
 lesions, 90
No special type (NST), 131
Nuclear pleomorphism, 101
- O**
Obliterative mastitis, 51
Oleic acid crystals, 54
One-step method, 37
Osteoclastic giant cells, 70
Osteoclast-like multinucleated cells, 138
- P**
p53, 159
p63, 100, 143, 145, 160
Paget's disease, 133, 148–149
Palpation, 34
Papillary apocrine hyperplasia, 106
Papillary carcinoma, 19, 145
Papillary carcinoma in situ, 112–116
Papillary DCIS, 127
Papillary lesions, 70, 103, 178, 180
Papillary tissue fragments, 103, 104, 120
Papilloma, 13, 85, 110
 with DCIS, 20
PASH. *See* Pseudoangiomatous stromal hyperplasia (PASH)
Peripheral palisading, 88
Phyllodes tumors, 12, 69, 73–77, 181
 borderline, 75
 malignant, 75
Plasmacytoid cells, 127
Pleomorphic adenoma, 70
Pleomorphic lobular carcinoma, 136
Polyacrylamide gel, 129
Polymerase chain reaction (PCR), 169
PR. *See* Progesterone receptor (PR)
Pregnancy, 3–4
Probabilistic approach, 90
Progesterone receptor (PR), 163, 171, 173
Proliferating cell nuclear antigen (PCNA), 159
Proliferative activity, 159
Pseudoangiomatous stromal hyperplasia (PASH), 69, 78–81, 181
- R**
Radial scar/complex sclerosing lesions, 60, 61
Radial scars, 63, 108, 110, 137
Reporting, 39–40
- S**
Sarcoidosis, 52
Sarcomas, 143
Sclerosing adenosis, 10, 62, 85, 87
Secondary slit-like lumina, 115
Secretory carcinoma, 133, 146, 147
Sensitivity, 178
Sentinel node, 151
Silver in situ hybridization (SISH), 172
Smears, 37–39
Smooth muscle actin (SMA), 163
Solid papillary carcinoma, 116–119, 127
Solid patterns, 91
Specificity, 178
Spindle cell carcinoma, 132
Squamous cell carcinoma, 132
Squamous cells, 25, 50
Squamous metaplasia, 132, 142
Staining, 39
Stellate tissue fragments, 104, 107, 110, 112
Stromal fragments, 73, 79, 99, 181
Stromal myxoid changes, 123
Stromal overgrowth, 181
Subareolar abscess, 50, 55
Suspensory ligaments of Cooper, 1
Synaptophysin, 117
Syncytial groupings, 140
Syncytial tissue fragments, 144
- T**
Technetium-labeled sulfur colloid, 151
Thelarche, 2
ThinPrep, 43
Tissue banking, 174

Triple approach, 134
Triple assessment, 31, 182, 185
Triple-negative, 172
Tuberculosis, 51
Tuberculous mastitis, 9
Tubular adenoma, 69
Tubular carcinoma, 22, 132, 136
Tubular structures, 100
Tubule formation, 101
Two-step method, 38

U

Ultrasound guided FNAC, 35
Usual ductal hyperplasia (UDH), 16, 63

V

Vacuum-assisted breast biopsy, 177